Category Archives: Editors Choice

The Sophia Lichtjesdiner Lights the Way to Genetic Patches

"Het

On Saturday 7 December, the ninth edition of the Sophia Lichtjesdiner took place, a benefit gala organised for and by the “Friends of Sophia”. This year, our department had the unique opportunity to present one of our research lines during the auction.

During a spectacular evening in the Laurenskerk, Ype Elgersma told the 400-strong audience about the “genetic patches” that he, together with Annelot van Esbroeck and their research team, wants to develop. With an efficient screening pipeline, they hope to develop personalized antisense oligonucleotides (ASOs, a form of RNA therapy) to treat ultra-rare developmental disorders. After a pitch of only two minutes, the auctioneer encouraged the audience to show their support by raising their hands. “As many hands as possible in the air for 25,000 euros per hand”, after which dozens of hands went up in the air.

This year, the Lichtjesdiner reached a record amount of 1.7 million euros! Of this amount, an impressive 500,000 euros has been reserved for the development of the “genetic patches” by Ype and Annelot. Thanks to this support, they can further develop their pipeline for personalized ASOs in the coming years. “This is not only support for research into innovative therapies, but also hope for parents and children for whom no other options are currently available,” says Ype.

ENCORE receives €60.000 from the vASN for Angelman syndrome research

"ENCORE

On November 23, 2024, the information day of the Association Angelman Syndrome Netherlands (vASN) took place. The members, donors and relations raised a large amount through fundraising campaigns and donations.

The ENCORE expertise centre has been presented with a cheque for €60,000 for the implementation of scientific research into Angelman syndrome.

During the annual information day, the latest developments in the field of Angelman syndrome are discussed, both in the field of (scientific) research and in the field of support in daily life.

For more information about the association, please visit https://www.angelmansyndroom.nl/.

The CAMK2 Outcome Measures Study has officially started!

"De

The CAMK2 Outcome Measures Study has officially started!

This month, the first two CAMK2 families traveled all the way from Italy to the Erasmus MC to participate in our efforts to identify feasible outcome measures for future intervention trials.
As a proof-of-concept, we are focusing on patients with two specific gain-of-function mutations in the CAMK2A and beta isoform. During their stay, the families visited our Child Brain Lab and were seen by our multi-disciplinary CAMK2 expert team which consists of a child psychiatry team, speech-language therapist, physical therapists, pediatric neurologist, and developmental & genetic pediatrician.

We are grateful to the families for participating in this study and look forward to meeting more members of the CAMK2 community in the coming years.

This project is funded by the Dutch Brain Foundation.

Aware of patients with a CAMK2B (Pro139Leu) or CAMK2A (Thr286XX) disorder? Please contact our team: camk2disorders@erasmusmc.nl.

ASA conference Coventry 2024

"ASA

On August 1 and 2, 2024, several members of the ENCORE Expertise Center for AS attended the ASA Scientific Conference, this time held in Coventry, UK.

It was an inspiring meeting with reunions of familiar faces and interesting presentations. Edwin Mientjes, Doesjka Hagenaar, Karen Bindels-de Heus and Marie-Claire de Wit also gave a presentation on their research. Karen was surprised by the ASA board with a Certificate of Gratitude for her recent promotion. We also had a useful meeting with our partners from the growing European network for AS.

Tour de Bunzl cycles for the Angelman Association

"Tour

On September 15, 2024, a huge amount of money was raised for the Angelman association during the Tour de Bunzl: €40,818!

Bunzl Nederland organizes this annual cycling tour through the hills of Valkenburg. A group of employees of one of the Bunzl companies cycle along. The sponsored money is generated by various suppliers who donate a lot of money to a good cause. This year, the Angelman Syndrome was chosen. The colleagues of Angel Saar's mother, who works at King - Bunzl in Tiel, also participated this year for this fantastic cause. At the end of the ride, the check was presented to the association under the watchful eye of the chairman, the treasurer, Angel Saar and Saar's mother.

Hora est! Promotion Karen Bindels-de Heus

"Hora

On July 3, 2024, pediatrician-EAA Karen Bindels-de Heus successfully defended her thesis “Angelman Syndrome in Children”.

In several studies she investigated the natural course of Angelman Syndrome (AS) in children with specific attention to development, epilepsy, sleep, eating behavior, growth, puberty, bone quality of children and quality of life of parents. She and her team also conducted a study on the effect of behavioral treatment of sleep problems in children. Finally, she described which new tests for neurocognitive functioning and growth are and are not feasible in children with AS. She especially thanked all children with AS and their parents for their trust in the ENCORE Expertise Center and sharing their knowledge and experience!

You can access her dissertation at Angelman Syndrome in Children (ogc.nl). If you are interested in a paper version of the dissertation, please contact us at angelman@erasmusmc.nl

It was a great day for the ENCORE Expertise Center for AS!

FACE-NF1 – ‘MultiFACEt’ approach to predict NF1 development – ​​launches with funding from LetsbeatNF

"FACE-NF1

The complex course of NF1 unraveled from different perspectives. Using clinical data, hereditary factors and biomarkers, we develop a personal risk profile for people with NF1-related plexiform neurofibromas for tailor-made treatment advice.

With a combination of clinical, genetic and biological information, we predict how benign and malignant tumors develop in people with NF1. This helps to improve treatments and follow-up in the future. The strength of the research lies in setting up a national system where all information about NF1 patients will be entered and stored (a database), including the storage of tissue material, which will be secured after an intervention or operation (a biobank).

We are still looking for a PhD candidate on this project. Check the vacancy page for more information.

Principal investigators: Rianne Oostenbrink/Walter Taal

The Sophia bus on RTV Rijnmond!

"De

On Friday 15 March, RTV Rijnmond joined Sabine Mous and Kamil Hiralal in the Sophia bus to see how we use it for research. The Sophia bus is an initiative from ENCORE scientists with the aim of reducing the pressure to participate in research.

Continue Reading